MNKD 2017 Annual Report

PART II Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Common Stock Market Price Our common stock has been traded on The NASDAQ Global Market under the symbol “MNKD” since July 28, 2004. The following table sets forth for the quarterly periods indicated, the high and low sales prices for our common stock as reported by The NASDAQ Global Market (adjusted for the Reverse Stock Split effective March 3, 2017). High Low Year ended December 31, 2017 First quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 3.61 $1.44 Second quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1.88 $0.67 Third quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2.35 $1.09 Fourth quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 6.96 $2.01 Year ended December 31, 2016 First quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $11.20 $3.20 Second quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $10.15 $4.25 Third quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 6.05 $2.75 Fourth quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4.35 $2.05 The closing sales price of our common stock on The NASDAQ Global Market was $2.61 on February 9, 2018 and there were 109 registered holders of record as of that date. Performance Measurement Comparison The material in this section is not “soliciting material,” is not deemed “filed” with the SEC and shall not be incorporated by reference by any general statement incorporating by reference this Annual Report on Form 10-K into any of our filings under the Securities Act, or the Exchange Act, except to the extent we specifically incorporate this section by reference. The following graph illustrates a comparison of the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i) The NASDAQ Composite Index and (ii) The NASDAQ Biotechnology Index. The graph assumes a $100 investment, on December 31, 2012, in (i) our common stock, (ii) the securities comprising The NASDAQ Composite Index and (iii) the securities comprising The NASDAQ Biotechnology Index. 46